Jennison Associates LLC Reduces Position in Teva Pharmaceutical Industries Ltd. $TEVA

Posted by Francis Steltz on Jul 21st, 2026

Jennison Associates LLC lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 6.1% during the 1st quarter, HoldingsChannel reports. The fund owned 1,439,151 shares of the company’s stock after selling 94,220 shares during the period. Jennison Associates LLC’s holdings in Teva Pharmaceutical Industries were worth $43,347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. raised its position in Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the period. Wellington Management Group LLP lifted its stake in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after buying an additional 5,917,423 shares during the period. Finally, Schroder Investment Management Group boosted its position in Teva Pharmaceutical Industries by 261.1% during the fourth quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock valued at $231,793,000 after buying an additional 5,370,253 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 3.3%

TEVA opened at $30.96 on Tuesday. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The business has a 50 day simple moving average of $33.66 and a two-hundred day simple moving average of $32.70. The firm has a market capitalization of $35.60 billion, a price-to-earnings ratio of 23.28, a PEG ratio of 3.38 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the completion of the sale, the executive vice president directly owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 465,931 shares of company stock valued at $16,332,989 over the last three months. Insiders own 0.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $41.78.

Get Our Latest Research Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.